BioMarin Pharmaceutical Inc. (BMRN) — Financial statements
Income statement, balance sheet, and cash flow for BioMarin Pharmaceutical Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 3,221↑12.9% | 2,854↑18.0% | 2,419↑15.4% | 2,096↑13.5% | 1,846 | |
| Cost of Revenue | 737↑27.0% | 580↑9.1% | 532↑5.8% | 503↑6.9% | 471 | |
| Gross Profit | 2,484↑9.3% | 2,274↑20.5% | 1,887↑18.5% | 1,593↑15.8% | 1,376 | |
| Operating Expenses | ||||||
| R&D Expenses | 922↑23.4% | 747↑0.1% | 747↑15.0% | 650↑3.3% | 629 | |
| General & Administrative Expenses | 1,153↑116.6% | 532↑31.8% | 404↑8.3% | 373↑5.2% | 354 | |
| Selling & Marketing Expenses | 124↓74.0% | 477↓2.4% | 488↑8.5% | 450↑11.2% | 405 | |
| SG&A Expenses | 1,277↑26.6% | 1,009↑13.1% | 892↑8.4% | 823↑8.4% | 759 | |
| Other Expenses | -248↓845.1% | 33↓46.5% | 62↑252.6% | -41↓158.3% | 70 | |
| Operating Expenses | 1,951↑9.0% | 1,789↑5.2% | 1,701↑18.8% | 1,432↓1.8% | 1,458 | |
| Total Costs & Expenses | 2,688↑13.4% | 2,370↑6.1% | 2,233↑15.4% | 1,935↑0.3% | 1,929 | |
| Operating Results | ||||||
| Operating Income | 533↑10.2% | 484↑160.6% | 186↑15.4% | 161↑295.5% | -82 | |
| Depreciation & Amortization | 80↓17.5% | 96↓7.6% | 104↑2.4% | 102↓5.6% | 108 | |
| EBITDA | 573↓11.9% | 651↑112.1% | 307↑15.6% | 265↑459.4% | 47 | |
| EBIT | 493↓11.0% | 554↑173.8% | 202↑23.9% | 163↑369.6% | -61 | |
| Interest & Other Income | ||||||
| Net Interest Income | 64↑3.0% | 62↑51.6% | 41↑1886.6% | 2↑142.5% | -5 | |
| Interest Income | 75↑0.0% | 75↑28.4% | 58↑223.5% | 18↑72.0% | 10 | |
| Interest Expense | 11↓14.0% | 13↓26.9% | 17↑8.5% | 16↑4.1% | 15 | |
| Non-Operating Income | 40↑157.4% | -70↓320.7% | -17↓587.6% | -2↑88.9% | -22 | |
| Other Income / Expenses | -51↓188.6% | 58↑1963.4% | 3↑124.5% | -11↓263.0% | 7 | |
| Income Before Tax | 482↓10.9% | 542↑187.3% | 189↑26.1% | 150↑298.5% | -75 | |
| Income Tax Expense | 134↑16.3% | 115↑449.3% | 21↑161.0% | 8↑171.1% | -11 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 349↓18.3% | 427↑154.6% | 168↑18.4% | 142↑320.9% | -64 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 349↓18.3% | 427↑154.6% | 168↑18.4% | 142↑320.9% | -64 | |
| Bottom-Line Net Income | 349↓19.6% | 434↑159.0% | 168↑18.4% | 142↑320.9% | -64 | |
| EPS (Basic) | 1.82↓19.1% | 2.25↑152.8% | 0.89↑17.1% | 0.76↑317.1% | -0.35 | |
| EPS (Diluted) | 1.80↓18.6% | 2.21↑151.1% | 0.88↑17.3% | 0.75↑314.3% | -0.35 | |
| Weighted Average Shares | 192↑0.9% | 190↑1.2% | 188↑1.4% | 185↑1.3% | 183 | |
| Weighted Average Diluted Shares | 197↑0.3% | 197↑2.7% | 192↑1.4% | 189↑3.3% | 183 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.